Side­lined at the FDA, As­traZeneca watch­es as new team seizes ri­val drug in $1.5B Re­lyp­sa buy­out

Back in April, the M&A buzz in biotech swung its spot­light to Re­lyp­sa, a com­pa­ny that had field­ed Veltas­sa (patiromer), a hy­per­kalemia drug that grabbed an ap­proval by the FDA last fall. At the time the lat­est ru­mors sur­faced, it sound­ed like the frus­trat­ed bid­ders for ri­val ZS Phar­ma – out­bid at the auc­tion by As­traZeneca — were dri­ving the chat­ter. But this morn­ing we hear that it’s Re­lyp­sa’s Eu­ro­pean part­ners at Galeni­ca who were the most mo­ti­vat­ed to com­plete a deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.